Le Tourneau, Christophe
Kurzrock, Razelle
Article History
First Online: 11 October 2016
Competing interests
: C.L.T. has received consultant fees from Debiopharm, GamaMabs, Merck Serono, MSD and Novartis. R.K. receives funding from Foundation Medicine, Genentech, Guardant, Merck Serono, Pfizer and Sequenom, consultant fees from Actuate Therapeutics and X-Biotech, and owns equity in CureMatch and Novena.